OTC: CLRPF - Clarity Pharmaceuticals Ltd

Yield per half year: -61.5%
Dividend yield: 0%
Sector: Healthcare

Share chart Clarity Pharmaceuticals Ltd

Extended chart Simple chart
Financial Markets by TradingView

About Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.

more details
The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.claritypharmaceuticals.com
Цена ао 1.5
Change price per day: +0% (1.498)
Change price per week: -1.64% (1.523)
Change price per month: +6.62% (1.405)
Change price per 3 month: -34.87% (2.3)
Change price per half year: -61.5% (3.891)
Change price per year: -51.36% (3.08)
Change price per year to date: -44.62% (2.705)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 10.16 1
P/E 0 0
EV/EBITDA 0 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -31.35 0
ROE, % -33.85 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 0 0
Yield EPS, % 1.72 1
Total: 4.2
More

Institutions Volume Share, %
PFM Multi Manager Series-International Equity Fd 24827 0.01



Head Job title Payment Year of birth
Dr. Alan John Taylor Ph.D. Executive Chairman 567.72k
Dr. Colin David Biggin Ph.D. MD, CEO & Executive Director 455.18k
Mr. David K. Green BEc., CA Chief Financial Officer 159.32k
Mr. Shaemus Gleason Executive Vice President of Operations N/A
Dr. Matthew Harris BSc., M.B.A., Ph.D. Chief Scientific Officer 130.94k
Michelle Parker Chief Clinical Officer N/A
Mr. Robert Vickery Company Secretary 109.28k
Ms. Lisa Sadetskaya Director of Corporate Communications.
Mary Bennett Head of Human Resource
Dr. Othon Gervasio Chief Medical Officer

Address: Australia, Sydney, National Innovation Centre - open in Google maps, open in Yandex maps
Website: https://www.claritypharmaceuticals.com